Hangar
发表于 2025-3-25 05:54:48
http://reply.papertrans.cn/93/9261/926021/926021_21.png
Blasphemy
发表于 2025-3-25 09:46:22
the chronological order of publication. Each article reviewed includes a succinct overview of methodology and the results, followed by a discussion that puts the results into clinical context. All articles ar978-3-031-25619-6978-3-031-25620-2
Monolithic
发表于 2025-3-25 12:17:53
http://reply.papertrans.cn/93/9261/926021/926021_23.png
注意力集中
发表于 2025-3-25 19:09:57
http://reply.papertrans.cn/93/9261/926021/926021_24.png
RLS898
发表于 2025-3-25 20:35:32
http://reply.papertrans.cn/93/9261/926021/926021_25.png
acheon
发表于 2025-3-26 03:30:34
Thrombolysis in Acute Strokes (ECASS-II)-1998ith a clot dissolver called tissue plasminogen activator (TPA) . The ECASS II trial was one of the first trials to review the safety and efficacy of alteplase (recombinant TPA) which to this day is still one of the first line therapies for ischemic CVA.
MITE
发表于 2025-3-26 05:20:51
http://reply.papertrans.cn/93/9261/926021/926021_27.png
Lice692
发表于 2025-3-26 11:18:58
http://reply.papertrans.cn/93/9261/926021/926021_28.png
不整齐
发表于 2025-3-26 12:44:27
http://reply.papertrans.cn/93/9261/926021/926021_29.png
Absenteeism
发表于 2025-3-26 19:21:17
Empagliflozin in Diastolic Heart Failure (EMPEROR)-2021unction, among other pathophysiologic abnormalities . Multiple trials in patients with HFpEF have failed to reach their primary endpoints. The EMPEROR-PRESERVED trial is the first trial to have reach its primary outcome in patients with HFpEF.